Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Imaging Mitochondrial Complex-I in Alcohol Use Disorder

11. september 2026 opdateret af: Rajesh Narendran

Imaging Mitochondrial Complex-I With [F-18]BCPP-EF Positron Emission Tomography (PET) in Alcohol Use Disorder (AUD)

Studies proposed in this application will image mitochondrial Complex-I (MCI-I) and cerebral glucose metabolism (CGM) in alcohol use disorder (AUD) and matched healthy controls

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This study uses [18F]BCPP-EF and [18F]FDG positron emission tomography (PET) to image mitochondrial complex I and cerebral glucose metabolism (CGM) in subjects with alcohol use disorder (AUD) and healthy controls (HC). Correlating PET outcome measures with relapse to alcohol in this study will clarify the mechanisms by which abnormal brain energetics modulate addictive behaviors.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

100

Fase

  • Tidlig fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forenede Stater, 15213
        • Rekruttering
        • University of Pittsburgh
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen

Tager imod sunde frivillige

Ja

Beskrivelse

Alcohol use disorders (AUD)

  1. Males or females between 18 and 55 years old
  2. fulfill DSM-5 criteria for alcohol use disorder
  3. History of NIAAA heavy drinking (for males, routinely consuming more than 4 drinks on any day or more than 14 drinks per week; for females, routinely consuming more than 3 drinks on any day or more than 7 drinks per week) in the past 30 days
  4. No other major DSM-5 psychiatric disorders including schizophrenia, schizoaffective disorder, bipolar disorder, developmental disorders, or current depressive disorders (unless they are related to alcohol intoxication, withdrawal, or an alcohol- induced mood disorder).
  5. No other DSM-5 substance use disorders including opioids, cocaine, amphetamines, sedative-hypnotics, hallucinogens, and inhalants. Subjects with moderate and severe DSM-5 cannabis and tobacco use disorder will also be excluded;
  6. Subjects not currently on psychotropic or medical medications that can influence binding to MC-I (e.g., metformin) or CGM (e.g., insulin, GLP-1 agonists), or increase the risks associated with an arterial line (e.g., warfarin, clopidogrel, aspirin, naproxen, ibuprofen, etc.).
  7. No medical disorders that can influence the PET outcome measures (for example, MC-I binding is altered in Parkinson's disease, mild or major neurocognitive disorders, and mitochondrial disorders; CGM is altered in diabetes, severe hyperlipidemia, hypertension, obesity), increase the risks associated with blood sampling (anemia), or placement of an arterial line (history of deep vein thrombosis, pulmonary embolism, thrombocytopenia or thrombocytosis) for PET
  8. Not currently pregnant or breast-feeding
  9. Not currently employed as a radiation worker; or has participated in a radiation-related research protocol within the previous year such that the total cumulative annual radiation dose (i.e., from participation in the previous radioactive drug study [studies] and this study) would exceed the radiation dose limits specified in the FDA regulations (i.e., 21 CFR 361.1) that govern the research use of radiotracers
  10. No medical or psychiatric contraindications to undergo an MRI scan (such as ferromagnetic tattoos/piercings, implants, medical equipment, history of gunshot, and claustrophobia).

Healthy controls (HC)

  1. Males or females between 18 and 55 years old
  2. No current or past DSM-5 psychiatric or substance use disorders other than tobacco use disorder
  3. No history of heavy drinking as defined using NIAAA criteria in the past year
  4. 5 to 10 above.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Grundvidenskab
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: PET
Positron Emission Tomography Scans
Radiotracer to measure binding to mitochondria complex -I
Radiotracer to measure cerebral glucose metabolism

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Dorsolateral prefrontal cortex [F-18]BCPP-EF VT
Tidsramme: Baseline scan (time 0)
VT is the volume of distribution expressed relative to total plasma radioligand concentration, mL/cm3
Baseline scan (time 0)
Orbitofrontal cortex [F-18]BCPP-EF VT
Tidsramme: Baseline scan (time 0)
VT is the volume of distribution expressed relative to total plasma radioligand concentration in mL/cm3
Baseline scan (time 0)
Medial Prefrontal Cortex [F-18]BCPP-EF VT
Tidsramme: Baseline scan (time 0)
VT is the volume of distribution expressed relative to total plasma radioligand concentration, mL/cm3
Baseline scan (time 0)
Dorsolateral prefrontal cortex [F-18]FDG SUVR
Tidsramme: Baseline scan (time 0)
SUVR is the standardized uptake value ratio with whole brain activity as a reference region, unitless
Baseline scan (time 0)
Orbitofrontal cortex [F-18]FDG SUVR
Tidsramme: Baseline scan (time 0)
SUVR is the standardized uptake value ratio with whole brain activity as a reference region, unitless
Baseline scan (time 0)
Medial Prefrontal Cortex [F-18]FDG SUVR
Tidsramme: Baseline scan (time 0)
SUVR is the standardized uptake value ratio with whole brain activity as a reference region, unitless
Baseline scan (time 0)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Relapse to alcohol severity measure
Tidsramme: during 8-week follow up
Total number of ETG-negative urines (0 to 16)
during 8-week follow up
Penn Alcohol Craving Scale (PACS)
Tidsramme: during 8-week follow up
Mean weekly PACS scores (range 0 to 30; higher scores indicate more craving)
during 8-week follow up

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Categorical relapse to alcohol
Tidsramme: 8-week follow up
Abstained v Relapsed v Drop-out
8-week follow up
TIme to relapse
Tidsramme: during 8 week follow up
in weeks (0 to 8)
during 8 week follow up
Perceived Stress Scale (PSS)
Tidsramme: during 8-week follow up
Mean weekly PSS scores (0 to 40; higher scores indicate more stress)
during 8-week follow up
Prefrontal Cortical Thickness
Tidsramme: Baseline scan (time 0)
MRI-derived cortical thickness measure derived using FreeSurfer, in mm
Baseline scan (time 0)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Rajesh Narendran, MD, University of Pittsburgh

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

30. september 2026

Primær færdiggørelse (Anslået)

31. december 2032

Studieafslutning (Anslået)

31. december 2032

Datoer for studieregistrering

Først indsendt

11. september 2026

Først indsendt, der opfyldte QC-kriterier

11. september 2026

Først opslået (Faktiske)

17. september 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • STUDY24030081
  • R01AA031453-01A1 (Andet bevillings-/finansieringsnummer: NIAAA)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

All individual participant data that underlie the results reported in the publication or upon study completion will be shared after de-identification via NIAAA Data Archive

IPD-delingstidsramme

Upon publication or study completion Data will be available as long as it is archived as per NIAAA Data Archive policy

IPD-delingsadgangskriterier

Aavailable as per NIAAA Data Archive policy

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .